Healthcare-Associated Infections
DZIF scientists aim to develop new strategies against the development and spread of antibiotic resistance.
Antimicrobial resistance is one of the greatest challenges facing modern medicine worldwide. Bacterial pathogens from the so-called ESKAPE spectrum, which frequently cause severe and difficult-to-treat infections are particularly problematic are. These include methicillin-resistant Staphylococcus aureus (MRSA), extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-producers), carbapenemase-producing Enterobacterales (CPE), vancomycin-resistant enterococci (VRE), hypervirulent Klebsiella pneumoniae, and Pseudomonas aeruginosa, among others. Many of these infections occur in the context of medical treatment and develop during a stay in healthcare facilities.
The research area "Healthcare-Associated Infections" addresses three key challenges in the field of infectious diseases and antimicrobial resistance:
- Progressing antimicrobial resistance facing restricted treatment options
The global rise in resistant pathogens significantly complicates the treatment of infections. While fewer effective antibiotics are available, existing treatments must be preserved through responsible use and supplemented by new therapeutic strategies.
- Delayed or insufficient diagnostics
Conventional diagnostic procedures often take a long time until the results are available. This hinders targeted treatment and encourages the use of broad-spectrum antibiotics.
- Inadequate understanding of transmission and individual risks
The dynamics of resistance development and transmission between patients, facilities, and sectors are not well understood. Longitudinal and cross-sectoral analyses of integrated clinical and microbiological data are necessary to identify risk profiles and tailor targeted prevention strategies.
To address the global challenge of antimicrobial resistance (AMR), the research area "Healthcare-Associated Infections" focuses on three central themes.
Central Themes
-
Prevention and therapy of infections with multidrug-resistant bacteria
-
Our IT-based prognosis models, high-resolution diagnostic procedures and novel therapeutic approaches aim at stopping the spread of multidrug-resistant pathogens.
-
Optimisation of or alternatives to antibiotic-based therapies
-
Many pathogens that lead to problematic infections in clinics are brought into the clinics by humans. DZIF researchers aim to develop intervention strategies to eliminate these bacteria in time, before a person becomes a risk patient.
-
Surveillance of healthcare-associated multidrug-resistant bacteria
-
Genome sequencing is used to investigate the mechanisms and spread of healthcare-associated resistant bacterial strains in order to prevent the development of resistance and infections with multi-resistant pathogens.